Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Koen van Besien et al.|New England Journal of Medicine|2012Cited by 1.1k
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing ResultsMichael C. Heinrich, Laurence H. Baker, Cathryn Rankin et al.|JAMA Oncology|2017Cited by 126
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapyAmy J. Wisdom, David G. Kirsch, Yvonne M. Mowery et al.|Nature Communications|2020Cited by 112
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H. Strand, Graham A. Colditz, Belén Rivero‐Gutiérrez et al.|Cancer Cell|2022Cited by 88
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Justine C. Rutter et al.|Nature Cancer|2022Cited by 42